--- title: "Pharming Group NV (PHARM) news: delisting" url: "https://aibio.space/companies/pharming/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PHARM delisting news: Pharming lifts its stake in Abliva to 92.70 percent and extends cash offer to March 6." --- PHARM Pharming Group NV EURONEXT · Netherlands # Pharming Group NV (PHARM) news PHARM delisting news Listings · 2025-02-20 ## [Pharming lifts its stake in Abliva to 92.70 percent and extends cash offer to March 6](https://aibio.space/news/pharming-lifts-stake-abliva-92-70-percent-extends-cash-offer-march-6/) Pharming's subsidiary now controls 92.70 percent of Abliva through its SEK 0.45 cash offer, and it has extended the acceptance period to March 6, 2025 for holders who have not yet tendered. Pharming plans a compulsory acquisition of the rest and a delisting from Nasdaq Stockholm. ## Latest Pharming Group NV news We have not published a story on Pharming Group NV yet. When there is news, it will appear here. ## Pharming Group NV at a glance - **Ticker**: PHARM - **Listing**: EURONEXT - **Country**: Netherlands - **Cash, Dec 31, 2025**: $145.3 million ### Related companies - [ProQR Therapeutics](https://aibio.space/companies/proqr-therapeutics-n-v/) NASDAQ: PRQR - [NewAmsterdam Pharma Company](https://aibio.space/companies/newamsterdam-pharma-n-v/) NASDAQ: NAMS - [uniQure](https://aibio.space/companies/uniqure-n-v/) NASDAQ: QURE - [argenx](https://aibio.space/companies/argenx/) EURONEXT: ARGX - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) NASDAQ: PHVS ### Also on EURONEXT - [UCB](https://aibio.space/companies/ucb-s-a/) UCB - [Sensorion SA](https://aibio.space/companies/sensorion/) ALSEN - [Oncodesign Precision Medicine](https://aibio.space/companies/oncodesign-precision-medicine-s-a/) ALOPM - [AB Science SA](https://aibio.space/companies/science/) AB - [Poxel SA](https://aibio.space/companies/poxel/) POXEL - [Adocia SA](https://aibio.space/companies/adocia/) ADOC ## What Pharming Group NV does Pharming Group NV is a global biotechnology company that develops and commercializes therapies for rare and ultra-rare diseases, focused on immunological and genetic conditions. It currently commercializes two approved therapies. RUCONEST is a recombinant C1 esterase inhibitor protein replacement therapy for acute hereditary angioedema (HAE) attacks in adult and adolescent patients, approved in the European Economic Area and the United Kingdom in 2010 and in the United States in 2014, with the US as its commercial focus. Joenja (leniolisib) is an oral PI3K delta inhibitor for activated phosphoinositide 3-kinase delta syndrome (APDS), approved in the United States, United Kingdom, Australia and Israel, and in Japan for patients aged 4 years and older. The pipeline includes leniolisib in two Phase II studies for primary immunodeficiencies with immune dysregulation. Through its 2025 acquisition of Abliva AB, the company gained KL1333, now named napazimone, a potential first-in-disease therapy for mtDNA-driven primary mitochondrial disease. Napazimone is in a pivotal trial and passed a futility analysis on its two primary endpoints. For HAE, the text says the US is the core commercial opportunity and cites a diagnosed population of 2.67 per 100,000 in recent real-world US claims analyses. | Product or program | What it is | Stage | |---|---|---| | RUCONEST (rhC1-INH) | Recombinant C1 esterase inhibitor for acute hereditary angioedema attacks | approved in the EEA, UK and US | | Joenja (leniolisib) | Oral PI3K delta inhibitor for activated phosphoinositide 3-kinase delta syndrome | approved in the US, UK, Australia, Israel and Japan | | Leniolisib for immune dysregulation | Treatment for primary immunodeficiencies with immune dysregulation | Phase II | | Napazimone (KL1333) | Potential first-in-disease therapy for mtDNA-driven primary mitochondrial disease | pivotal clinical trial | Summarised from the company's [20-F filed Apr 2, 2026](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/pharm-20251231.htm). ## Pharming Group NV annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$376.1 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | [$297.2 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | | Research and development | [$100.4 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | [$83.1 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | | Net income (loss) | [$2.5 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | [-$11.8 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | | Cash from operations | [$54.7 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | [-$1.8 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | | Cash and equivalents | [$145.3 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | [$54.9 million](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $145.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Pharming Group NV Was Pharming Group NV delisted? Our latest story on this, dated Feb 20, 2025: "Pharming lifts its stake in Abliva to 92.70 percent and extends cash offer to March 6". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pharming-lifts-stake-abliva-92-70-percent-extends-cash-offer-march-6/). What is the ticker symbol of Pharming Group NV? Pharming Group NV trades under the ticker PHARM on EURONEXT. Where is Pharming Group NV listed? Pharming Group NV is listed on EURONEXT. Our directory also records these other listings: DUS:PHGN; FWB:PHGN; GETTEX:PHGN; HAM:PHGN; HAN:PHGN; LS:A1H65A; LSIN:0QCO; LSX:A1H65A; MUN:PHGN; NASDAQ:PHAR; OTC:PHGUF; SWB:PHGN; TRADEGATE:PHGN; XETR:PHGN. What is the SEC CIK of Pharming Group NV? The SEC Central Index Key (CIK) for Pharming Group NV is 1828316. Its filings are on SEC EDGAR. How many shares does Pharming Group NV have outstanding? 701,680,440 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-02. Which country or territory is Pharming Group NV listed under? Our directory records Pharming Group NV under Netherlands. What does Pharming Group NV do? Our directory classifies Pharming Group NV as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Pharming Group NV? The ISIN recorded for Pharming Group NV is NL0010391025. Does aibio.space cover Pharming Group NV? aibio.space lists Pharming Group NV among 2,820 public biotech companies and publishes its news here as stories appear. Where is Pharming Group NV incorporated? SEC records list its state or country of incorporation as P7. What does Pharming Group NV develop? Pharming Group NV is a global biotechnology company that develops and commercializes therapies for rare and ultra-rare diseases, focused on immunological and genetic conditions. It currently commercializes two approved therapies. What is RUCONEST (rhC1-INH) from Pharming Group NV? RUCONEST (rhC1-INH): Recombinant C1 esterase inhibitor for acute hereditary angioedema attacks Stage: approved in the EEA, UK and US. What is Joenja (leniolisib) from Pharming Group NV? Joenja (leniolisib): Oral PI3K delta inhibitor for activated phosphoinositide 3-kinase delta syndrome Stage: approved in the US, UK, Australia, Israel and Japan. What was Pharming Group NV's revenue last year? $376.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Pharming Group NV profitable? Pharming Group NV reported net income of $2.5 million for the fiscal year ended Dec 31, 2025, and generated $54.7 million of cash from operations, per its annual report to the SEC. ## Investor discussion: Pharming Group NV Members talk about Pharming Group NV (PHARM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Pharming Group NV, newest first. Each line links the filing it comes from. 1. 2025-02-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000008/pharmingtechnologiesbvincr.htm) 2. 2025-02-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000006/pharmingtechnologiesbvdecl.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open EURONEXT:PHARM on TradingView](https://www.tradingview.com/symbols/EURONEXT-PHARM/). ## SEC filings and registration - **SEC name**: Pharming Group N.V. - **CIK**: 1828316 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PHAR (Nasdaq) - **State or country of incorporation**: P7 - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: DARWINWEG 24, LEIDEN, Netherlands, 2333 CR - **Phone**: 31 (0)71 5247 400 - **Shares outstanding**: 701,680,440 as of 2025-12-31 (20-F filed 2026-04-02) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000047/q3announcementpr.htm) filed 2026-10-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000045/pharmingpresentspositiveph.htm) filed 2026-10-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000043/pharmingannouncesceotransi.htm) filed 2026-09-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000039/pharmingannouncespositivep.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000037/fdaapprovespharmingsjoenja.htm) filed 2026-09-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000035/pharmingannouncescommercia.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm) filed 2026-07-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001828316), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Pharming Group NV is a public biotech or pharmaceutical company listed on EURONEXT under the ticker PHARM, recorded under Netherlands. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Pharming Group NV - **Ticker**: PHARM - **Listing**: EURONEXT - **Country or territory**: Netherlands - **Business scope**: Pharmaceuticals: Major - **ISIN**: NL0010391025 - **Other listed symbols**: DUS:PHGN; FWB:PHGN; GETTEX:PHGN; HAM:PHGN; HAN:PHGN; LS:A1H65A; LSIN:0QCO; LSX:A1H65A; MUN:PHGN; NASDAQ:PHAR; OTC:PHGUF; SWB:PHGN; TRADEGATE:PHGN; XETR:PHGN - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/EURONEXT-PHARM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pharming/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pharming Group NV (PHARM) news: delisting", 2026-10-31, https://aibio.space/companies/pharming/